Pharmacotherapy for major depression in children and adolescents

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


Major depression is a serious illness in children which adversely effects their social, academic, and emotional development. It is essential to identify safe and effective medication for the treatment of this disorder in youths. Only some selective serotonin reuptake inhibitors (citalopram, fluoxetine, sertraline) have demonstrated superiority to placebo on primary outcome measures in acute controlled treatment trials. This article will review acute efficacy studies as well as long-term studies of antidepressants for the treatment of childhood depression. Treatment recommendations are discussed and the issue of suicidality and antidepressants are addressed.

Original languageEnglish (US)
Pages (from-to)819-826
Number of pages8
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Issue number5
StatePublished - Jun 2005
Externally publishedYes


  • Antidepressants
  • Bupropion
  • Citalopram
  • Escitalopram
  • Fluoxetine
  • Major depression
  • Mirtazapine
  • Monoamine oxidase inhibitors
  • Nefazodone
  • Paroxetine
  • Selective serotonin reuptake inhibitors
  • Sertraline
  • Suicidality
  • Venlafaxine

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry


Dive into the research topics of 'Pharmacotherapy for major depression in children and adolescents'. Together they form a unique fingerprint.

Cite this